[go: up one dir, main page]

JO3732B1 - مشتقات 17-هيدروكسي-17بنتافلوروإيثيل-إسترا-4،9(10)-دين-11-أريل، طريقة لإنتاجها واستخدامها في معالجة الأمراض - Google Patents

مشتقات 17-هيدروكسي-17بنتافلوروإيثيل-إسترا-4،9(10)-دين-11-أريل، طريقة لإنتاجها واستخدامها في معالجة الأمراض

Info

Publication number
JO3732B1
JO3732B1 JOP/2016/0059A JOP20160059A JO3732B1 JO 3732 B1 JO3732 B1 JO 3732B1 JO P20160059 A JOP20160059 A JO P20160059A JO 3732 B1 JO3732 B1 JO 3732B1
Authority
JO
Jordan
Prior art keywords
diseases
treatment
production
estra
dien
Prior art date
Application number
JOP/2016/0059A
Other languages
English (en)
Inventor
Andrea Rotgeri Dr
Ulrich Klar Dr
Carsten M?Ller Dr
Wolfgang Schwede Dr
Wilhelm Bone Dr
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43383964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3732(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Application granted granted Critical
Publication of JO3732B1 publication Critical patent/JO3732B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق الاختراع الحالي بمشتقات 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl من الصيغة I مع تأثير يعارض progesterone وطريقة لإنتاجها، استخدامها في معالجة و/أو الوقاية من الأمراض واستخدامها في إنتاج منتجات طبية من أجل معالجة و/أو الوقاية من الأمراض، تحديدا أورام ليفية حميدة للرحم (أورام عضلية، ورم عضلي أملس بجدار الرحم)، انتشار بطانة الرحم خارج الرحم، نزف دموي كثيف في حالة الطمث، أورام سحائية، سرطان ثدي معتمد على هرمون وأمراض مصاحبة لسن اليأس أو للتحكم في الخصوبة ومنع الحمل الطارئ.
JOP/2016/0059A 2009-07-20 2016-03-28 مشتقات 17-هيدروكسي-17بنتافلوروإيثيل-إسترا-4،9(10)-دين-11-أريل، طريقة لإنتاجها واستخدامها في معالجة الأمراض JO3732B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102009034362A DE102009034362A1 (de) 2009-07-20 2009-07-20 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten

Publications (1)

Publication Number Publication Date
JO3732B1 true JO3732B1 (ar) 2021-01-31

Family

ID=43383964

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2010/0255A JO3009B1 (ar) 2009-07-20 2010-07-18 مشتقات 17-هيدروكسي-17بنتافلوروإيثيل-إسترا-4،9(10)-دين-11-أريل، طريقة لإنتاجها واستخدامها في معالجة الأمراض
JOP/2016/0059A JO3732B1 (ar) 2009-07-20 2016-03-28 مشتقات 17-هيدروكسي-17بنتافلوروإيثيل-إسترا-4،9(10)-دين-11-أريل، طريقة لإنتاجها واستخدامها في معالجة الأمراض

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JOP/2010/0255A JO3009B1 (ar) 2009-07-20 2010-07-18 مشتقات 17-هيدروكسي-17بنتافلوروإيثيل-إسترا-4،9(10)-دين-11-أريل، طريقة لإنتاجها واستخدامها في معالجة الأمراض

Country Status (47)

Country Link
US (4) US20120149670A1 (ar)
EP (4) EP3252069B1 (ar)
JP (3) JP5795312B2 (ar)
KR (2) KR101687853B1 (ar)
CN (1) CN102482317B (ar)
AR (1) AR077491A1 (ar)
AU (1) AU2010275849B2 (ar)
BR (1) BR112012001344B8 (ar)
CA (1) CA2768407C (ar)
CL (1) CL2012000166A1 (ar)
CO (1) CO6491067A2 (ar)
CR (2) CR20170091A (ar)
CU (1) CU20120012A7 (ar)
CY (3) CY1114260T1 (ar)
DE (1) DE102009034362A1 (ar)
DK (3) DK3252069T3 (ar)
DO (2) DOP2012000015A (ar)
EA (2) EA021946B1 (ar)
EC (2) ECSP12011616A (ar)
ES (3) ES2416461T3 (ar)
GT (1) GT201200012A (ar)
HN (1) HN2012000137A (ar)
HR (3) HRP20130558T1 (ar)
HU (2) HUE043757T2 (ar)
IL (1) IL216967B (ar)
IN (1) IN2012DN00598A (ar)
JO (2) JO3009B1 (ar)
LT (2) LT2623510T (ar)
MA (1) MA33445B1 (ar)
ME (2) ME03400B (ar)
MX (2) MX2012000930A (ar)
MY (1) MY179447A (ar)
NO (1) NO2623510T3 (ar)
NZ (2) NZ623417A (ar)
PE (2) PE20170084A1 (ar)
PL (3) PL3252069T3 (ar)
PT (3) PT2623510T (ar)
RS (1) RS52811B (ar)
SG (3) SG10201811830PA (ar)
SI (3) SI2623510T1 (ar)
TN (1) TN2012000028A1 (ar)
TR (1) TR201908600T4 (ar)
TW (1) TWI505830B (ar)
UA (1) UA106502C2 (ar)
UY (1) UY32791A (ar)
WO (1) WO2011009531A2 (ar)
ZA (1) ZA201201222B (ar)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102011088270A1 (de) 2011-12-12 2013-06-13 Bayer Intellectual Property Gmbh (11ß ,17ß)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on zur Behandlung von Morbus Charcot Marie Toot
EA032481B1 (ru) 2013-04-11 2019-06-28 Байер Фарма Акциенгезельшафт Дозированная форма антагониста рецептора прогестерона
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
EP3417863A1 (en) * 2015-05-18 2018-12-26 Bayer Pharma Aktiengesellschaft Selective progesterone receptor modulator (sprm) for use in the treatment of heavy menstrual bleeding
EP3214092A1 (en) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
EP3384913A1 (en) 2017-04-03 2018-10-10 Bayer Pharma Aktiengesellschaft Selective progesterone receptor modulators and stabilized estrogen level in patient
JP2021500359A (ja) * 2017-10-26 2021-01-07 クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド 選択的プロゲステロンの受容体モジュレーターの結晶形およびその製造方法
JP2025508967A (ja) 2022-03-01 2025-04-10 アルティン・バイオサイエンシーズ・コーポレイション 子宮筋腫の処置のためのｃｒｉｌａ（登録商標）およびｅｇｃｇ組成物

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2596395B1 (fr) * 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5272140A (en) 1987-01-23 1993-12-21 Akzo N.V. 11-aryl steroid derivatives
FR2620707B1 (fr) 1987-09-18 1989-12-08 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique a 3, 4 ou 6 chainons en position 17, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
FR2644789B1 (fr) 1989-03-22 1995-02-03 Roussel Uclaf Nouveaux steroides 19-nor, 3-ceto comportant une chaine en 17 aminosubstituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
DK0411733T3 (da) 1989-08-04 1999-06-28 Schering Ag 11-beta-aryl-gona-4,9-dien-3-oner
US5407928A (en) 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
CA2100514C (en) * 1992-07-29 2005-03-29 Johannes A. M. Hamersma 17-spiromethylene steroids
FR2718354B1 (fr) 1994-04-08 1996-05-03 Roussel Uclaf Application des composés antiglucocorticoïde pour la préparation de médicaments destinés à la prévention ou au traitement des manifestations liées au syndrome de sevrage des narcotiques et les compositions les renfermant.
DE4426601A1 (de) 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
EP1488794A3 (en) 1994-11-22 2005-04-20 Balance Pharmaceuticals, Inc. Methods of contraception
US6861415B2 (en) 1996-05-01 2005-03-01 The United States Of America As Represented By The Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
WO1998005679A2 (en) 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
FR2757400B1 (fr) 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US20010016578A1 (en) 1997-06-18 2001-08-23 Balance Pharmaceuticals, Inc. Compositions and methods for contraception and for treatment of benign gynecological disorders
JPH11171774A (ja) 1997-12-05 1999-06-29 Kyowa Hakko Kogyo Co Ltd 血球増多剤
PE20000129A1 (es) 1997-12-23 2000-03-11 Schering Ag 11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
AU3344099A (en) 1998-04-17 1999-11-08 Kyowa Hakko Kogyo Co. Ltd. Analgetic agent
US6172052B1 (en) * 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6476079B1 (en) 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
EP1157996A1 (de) 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
JP2004509131A (ja) 2000-09-18 2004-03-25 アプライド　リサーチ　システムズ　エーアールエス　ホールディング　ナームロゼ　フェンノートシャップ ２１−ヒドロキシ−６，１９−オキシドプロゲステロン（２１ｏｈ−６ｏｐ）の製造方法
PL366415A1 (en) 2000-10-18 2005-01-24 Schering Aktiengesellschaft Inhibition of the growth factor dependency of tumor cells
DE10051609A1 (de) 2000-10-18 2002-05-02 Schering Ag Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen
WO2002032430A1 (en) 2000-10-18 2002-04-25 Schering Aktiengesellschaft Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
US20020143000A1 (en) * 2001-01-09 2002-10-03 Christa Hegele-Hartung Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
JP2004520411A (ja) * 2001-01-09 2004-07-08 シエーリング アクチエンゲゼルシャフト 不妊症処理の間の促進された子宮内膜成熟を阻害するための抗ゲスタゲンの使用
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
DE10221034A1 (de) 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
DK1501859T3 (da) 2002-05-03 2006-03-06 Schering Ag 17 alfa-fluoralkyl- 11 beta-benzaldoxim-steroider, fremgangsmåde til fremstilling heraf, farmaceutiske præparater indeholdende disse steroider samt deres anvendelse til fremstilling af lægemidler
DE602005026290D1 (de) 2004-07-09 2011-03-24 Population Council Inc Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren
WO2006101009A1 (ja) 2005-03-18 2006-09-28 Hirose Engineering Co., Ltd. ナイルレッド系赤色発光化合物、及び発光素子
US20070105828A1 (en) 2005-08-19 2007-05-10 Glenmark Pharmaceuticals Limited Novel polymorph form M of mifepristone and process for its preparation
EP1862468A1 (de) 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
US20090075989A1 (en) * 2006-12-21 2009-03-19 Wolfgang Schwede Non-steroidal progesterone receptor modulators
WO2008105876A1 (en) 2007-03-01 2008-09-04 Prs Mediterranean Ltd. Uv resistant multilayered cellular confinement system
EP2123279A1 (de) 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten

Also Published As

Publication number Publication date
EA201200121A1 (ru) 2012-07-30
CR20120040A (es) 2012-03-12
ECSP18047708A (es) 2018-06-30
UA106502C2 (uk) 2014-09-10
TWI505830B (zh) 2015-11-01
MX338217B (es) 2016-04-07
PT2432798E (pt) 2013-06-28
IL216967A0 (en) 2012-02-29
HRP20130558T1 (hr) 2013-07-31
EA021946B1 (ru) 2015-10-30
EP2432798A2 (de) 2012-03-28
EP2623510A1 (de) 2013-08-07
US20150342962A1 (en) 2015-12-03
DK2623510T3 (en) 2017-12-04
CA2768407A1 (en) 2011-01-27
ES2730209T3 (es) 2019-11-08
CY1121926T1 (el) 2020-10-14
SI2432798T1 (sl) 2013-08-30
GT201200012A (es) 2013-10-15
US20170202857A1 (en) 2017-07-20
UY32791A (es) 2011-02-28
SG10201404159VA (en) 2014-10-30
SI3252069T1 (sl) 2019-06-28
AU2010275849B2 (en) 2014-12-18
NZ597639A (en) 2014-04-30
NO2623510T3 (ar) 2018-01-20
ME03400B (me) 2020-01-20
CU20120012A7 (es) 2012-07-31
EP2623510B1 (de) 2017-08-23
JO3009B1 (ar) 2016-09-05
US20120094969A1 (en) 2012-04-19
TW201105331A (en) 2011-02-16
SG177519A1 (en) 2012-02-28
CN102482317A (zh) 2012-05-30
KR101854059B1 (ko) 2018-05-02
PL2432798T3 (pl) 2013-08-30
HRP20171805T1 (hr) 2017-12-29
BR112012001344B1 (pt) 2020-09-24
TN2012000028A1 (en) 2013-09-19
PT3252069T (pt) 2019-06-18
DOP2012000015A (es) 2016-04-15
HUE037339T2 (hu) 2018-08-28
CY1114260T1 (el) 2016-08-31
PL2623510T3 (pl) 2018-02-28
EA025150B1 (ru) 2016-11-30
DK2432798T3 (da) 2013-07-01
ME01534B (me) 2014-04-20
CL2012000166A1 (es) 2012-08-31
KR101687853B1 (ko) 2016-12-19
WO2011009531A2 (de) 2011-01-27
MA33445B1 (ar) 2012-07-03
IN2012DN00598A (ar) 2015-06-12
EP3252069B1 (de) 2019-04-03
CY1119661T1 (el) 2018-04-04
US9717739B2 (en) 2017-08-01
HN2012000137A (es) 2015-05-04
WO2011009531A3 (de) 2011-04-28
CN102482317B (zh) 2014-09-17
CR20170091A (es) 2018-02-06
LT3252069T (lt) 2019-06-10
DOP2015000276A (es) 2018-04-15
SI2623510T1 (sl) 2017-12-29
DE102009034362A1 (de) 2011-01-27
HRP20191049T1 (hr) 2019-09-20
HUE043757T2 (hu) 2019-09-30
JP6130087B1 (ja) 2017-05-17
EP3252069A1 (de) 2017-12-06
NZ623417A (en) 2015-10-30
MY179447A (en) 2020-11-06
BR112012001344B8 (pt) 2021-05-25
EP2432798B1 (de) 2013-04-03
JP2015178522A (ja) 2015-10-08
KR20160093110A (ko) 2016-08-05
JP2017105813A (ja) 2017-06-15
AR077491A1 (es) 2011-08-31
BR112012001344A2 (pt) 2016-03-15
AU2010275849A1 (en) 2012-02-02
KR20120046182A (ko) 2012-05-09
PE20170084A1 (es) 2017-03-30
PT2623510T (pt) 2017-11-24
IL216967B (en) 2018-06-28
DK3252069T3 (da) 2019-06-24
TR201908600T4 (tr) 2019-07-22
HK1171456A1 (en) 2013-03-28
US10155004B2 (en) 2018-12-18
US8278469B2 (en) 2012-10-02
CA2768407C (en) 2017-10-24
EP3272763A1 (de) 2018-01-24
MX2012000930A (es) 2012-03-26
CO6491067A2 (es) 2012-07-31
PE20121085A1 (es) 2012-08-04
JP5795312B2 (ja) 2015-10-14
ECSP12011616A (es) 2012-02-29
CU24080B1 (ar) 2015-03-30
US20120149670A1 (en) 2012-06-14
ES2648292T3 (es) 2017-12-29
SG10201811830PA (en) 2019-02-27
LT2623510T (lt) 2017-12-11
EA201301263A1 (ru) 2014-08-29
PL3252069T3 (pl) 2019-09-30
ES2416461T3 (es) 2013-08-01
RS52811B (sr) 2013-10-31
JP2012533575A (ja) 2012-12-27
ZA201201222B (en) 2022-11-30

Similar Documents

Publication Publication Date Title
JO3732B1 (ar) مشتقات 17-هيدروكسي-17بنتافلوروإيثيل-إسترا-4،9(10)-دين-11-أريل، طريقة لإنتاجها واستخدامها في معالجة الأمراض
WO2011009530A3 (de) 17-hydroxy-17-pentafluorethyl-estra-4,9 (10)-dien-11-acyloxyalkylenphenyl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten
WO2011098437A3 (de) Progesteronrezeptorantagonisten
WO2011009534A3 (de) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten
PH12017502100A1 (en) Selective progesterone receptor modulator (sprm) regimen
MY172530A (en) Method for treating gynecological diseases
CY1121190T1 (el) Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης
NZ612295A (en) Novel 19-nor-steroids and their use for treating progesterone-dependent conditions
UA51785U (ru) Способ лечения сочетанных дисгормональных нарушений у женщин репродуктивного возраста